Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Although the research centered on mAChR4 within the gut, this signaling protein is also known to influence areas of the brain involved in habit formation, learning and addiction. Because individuals ...

1. Lou A, Elnenaei M, Liu E, et al. Evaluation of a novel albumin platelet product (APP) fibrosis index and three ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update New Data from Phase 2a Trial of Vanoglipel (DA-1241) Presented at The ...

Microphysiological systems help address the shortcomings of animal models for mAb development, and CN Bio is taking an active ...

A liquid biopsy involving a half-dozen cell-free and exosome-based circulating biomarkers showed high specificity and ...

The FDA has qualified the first AI-based drug development tool to support metabolic dysfunction-associated steatohepatitis clinical trials. The cloud-based tool, AI-Based Histologic Measurement of ...

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated ...

He warns against lean MASH, which occurs in people who are not overweight or obese (generally BMI or body mass index lower ...

Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...